Thomas B Hildebrandt, PsyD
img_Thomas B Hildebrandt
PROFESSOR | Psychiatry
PROFESSOR | Artificial Intelligence and Human Health
Are you a patient?
Multi-Disciplinary Training Area
Artificial Intelligence and Emerging Technologies in Medicine [AIET], Disease Mechanisms and Therapeutics (DMT), Neuroscience [NEU]

Internship, Clinical Psychology, UMDNJ-Robert Wood Johnson Medical School GME

Thomas Hildebrandt, PsyD, FAED, Chief of the Division of Eating and Weight Disorders

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Hildebrandt during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Board Service

  • Global Foundation for Eating Disorders

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Noom Inc. (Worksmart Labs)

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.